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OBJECTIVE: Patients with stage I non-small cell lung cancer who have undergone complete surgical resection
harbor a 30% risk for tumor recurrence. Thus, the identification of factors that are predictive for tumor
recurrence is urgently needed. The aim of this study was to test the prognostic value of serum albumin levels on
tumor recurrence in patients with stage I non-small cell lung cancer.
METHODS: Stage I non-small cell lung cancer patients who underwent complete surgical resection of the
primary tumor at Zhejiang Hospital were analyzed in this study. Serum albumin levels were measured before
surgery and once again after surgery in 101 histologically diagnosed non-small cell lung cancer patients.
Correlations between the pre- and post-operative serum albumin levels and various clinical demographics and
recurrence-free survival rates were analyzed.
RESULTS: Patients with pre-operative hypoalbuminemia (,3.5 g/dl) had a significantly worse survival rate than
patients with normal pre-operative serum albumin levels ($3.5 g/dl) (p=0.008). Patients with post-operative
hypoalbuminemia had a worse survival rate when compared with patients with normal post-operative serum
albumin levels (p=0.001). Cox multivariate analysis identified pre-operative hypoalbuminemia, post-operative
hypoalbuminemia and tumor size over 3 cm as independent negative prognostic factors for recurrence.
CONCLUSION: Serum albumin levels appear to be a significant independent prognostic factor for tumor
recurrence in patients with stage I non-small cell lung cancer who have undergone complete resection. Patient
pre-treatment and post-treatment serum albumin levels provide an easy and early means of discrimination
between patients with a higher risk for recurrence and patients with a low risk of recurrence.
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& INTRODUCTION
According to global cancer statistics, 10.9 million new
cancer cases are diagnosed each year, of which 1.35 million
are lung cancers. Approximately 6.7 million patients die of
cancer every year, and lung cancers are responsible for 1.18
million deaths annually (1). In 2012, lung cancer was the
most common cause of malignancy-related mortality world-
wide, and non-small cell lung cancer (NSCLC) accounted
for nearly 80% of all lung cancer deaths (2). Stage I tumors
have become more easily detected due to recent advances in
diagnostic techniques (3). However, despite the success of
surgical resection, more than one-third of patients with
stage I NSCLC die of disease recurrence within 5 years of
tumor resection (4). In addition, while adjuvant che-
motherapy administered after resection of stage II-IIIA
NSCLC is the standard of care, the survival benefit of
adjuvant chemotherapy for stage I NSCLC patients
remains controversial (5–8). Despite the high recurrence
rate, patients with stage I NSCLC are not routinely
recommended to undergo adjuvant chemotherapy outside
of clinical trials.
Based on the uncertainty regarding the value of adjuvant
chemotherapy treatment for stage I NSCLC patients after
undergoing surgical resection, risk factors for tumor
recurrence must be identified to guide patient management.
The identification of risk factors for recurrence in stage I
NSCLC patients who have undergone resection may
provide a more appropriate estimation of individual out-
comes and allow the optimization of patient stratification in
clinical trials, leading to more meaningful assessments in
these studies. The 7th edition of the TNM classification
(TNM7) for lung cancer was published in 2009 (9). Until
recently, few studies investigated patient survival and
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patterns of recurrence in stage I NSCLC patients who have
undergone resection (TNM7) (10–14).
Malnutrition commonly occurs in cancer patients who are
receiving treatment. Serum albumin is an objective para-
meter that closely correlates with the degree of malnutrition
and is a regularly used biomarker for long-term nutrition
status (15,16). Albumin is produced by the liver and
maintains intravascular oncotic pressure, facilitates trans-
port of substances and acts as a free radical scavenger.
In adult humans, the normal range of serum albumin is
3.5–5.0 g/dl, and patients with serum albumin levels
,3.5 g/dl are considered to be hypoalbuminemic (17,18).
Accumulating data has highlighted a correlation between
hypoalbuminemia and survival in cancer patients. A
prospective study conducted by the British United
Provident Association demonstrated that a decline in serum
albumin levels could be a manifestation of the disease
process of preclinical cancer (19). In other cohort studies,
investigators have reported additional examples of a
prognostic role for serum albumin levels in various kinds
of malignancies. Hypoalbuminemia has been reported as a
negative prognostic factor for survival in colorectal carci-
noma (20,21), gastric carcinoma (22), and breast cancer (23),
among other types of cancer.
Espinosa E et al. (24) also reported that in patients with
advanced NSCLC, low serum albumin levels correlate with
poor survival. However, to the best of our knowledge,
previous studies have not explored the prognostic value of
serum albumin levels on tumor recurrence in stage I NSCLC
patients who have undergone complete resection.
In this study, for the first time, we investigated the
predictive value of serum albumin for tumor recurrence in
stage I NSCLC patients who have undergone complete
resection. Pre-operative and post-operative serum albumin
levels were measured, and recurrence-free survival (RFS)
was considered to be the primary endpoint.
& PATIENTS AND METHODS
Inclusion criteria and enrollment
We conducted a retrospective study using in-patient
medical records of patients with stage I NSCLC who were
treated at Zhejiang Hospital in China. Our study protocol
was approved by the Ethics Committee of Zhejiang
Hospital, and all experiments were conducted in accordance
with the Declaration of Helsinki. The requirement for
informed consent was waived by the committee, as our
study was a retrospective review of patient records.
The records of 256 patients with stage I NSCLC admitted
to Zhejiang Hospital between January 2002 and December
2011 were reviewed based on the following inclusion
criteria: (i) patient was pathologically diagnosed with stage
I NSCLC (TNM 7); (ii) patient underwent pulmonary
lobectomy and systematic lymph node dissection; (iii)
patient displayed good performance status (ECOG
score#2); (iv) patient displayed normal renal, cardiac and
liver functions; (v) patient had complete pre-operative and
post-operative serum albumin level records; and (vi) patient
had complete follow-up data. Exclusion criteria consisted of
the following: (i) patient underwent neoadjuvant che-
motherapy or radiation therapy; (ii) patient underwent
adjuvant chemotherapy or radiation after the initial surgical
resection; (iii) patient post-operative death occurred within
30 days of surgery; and (iv) patient death was not caused by
cancer progression.
Definitions
Local recurrence was defined as tumor recurrence in
contiguous anatomical sites, including the ipsilateral hemi-
thorax and mediastinum, after the initial surgical resection.
Distant recurrence was defined as tumor recurrence in the
contralateral lung or outside of the hemithorax and
mediastinum after the initial surgical resection. Cancer
recurrence was confirmed histologically or radiographi-
cally. Pattern of recurrence was defined as all recurrences
discovered between the initial operation and death or the
final follow-up on record. RFS was defined as the duration
from the date of surgical resection to the date of the first
recurrence. Patients without recurrence at the last follow-up
or death were classified as censored observations. Body
mass index (BMI) was calculated as weight (kg)/height2
(m2). Patients with a BMI,20 are considered to be under-
weight; therefore, the BMI cut-off value was set at 20.
Serum albumin was estimated by employing the opti-
mized standard method recommended by Peters T Jr. (25).
Serum albumin levels $3.5 g/dl were considered to be
normal because this value corresponds to the lower extreme
range that is observed in a normal population using the
methods described above. Patients with serum albumin
levels ,3.5 g/dl were considered to be hypoalbuminemic.
Follow-up
Post-operatively, patients were examined at 3-month
intervals for the first year, at 6-month intervals for the
second year and annually thereafter on an outpatient basis.
The follow-up evaluation included a physical examination,
chest radiography and blood analysis. Whenever symptoms
or signs of recurrence were detected, further evaluations
were performed, which included computed tomography
scans of the chest and abdomen, brain magnetic resonance
imaging and bone scintigraphy. All patients were mon-
itored through March 2012.
Statistical Analysis
Statistical analysis was performed using the SPSS 17.0
software package. Survival rates were analyzed using the
Kaplan–Meier method and were compared using the log-
rank test. P-values for differences between groups of
patients were calculated using Fisher’s exact test (two-
tailed). Correlations between serum albumin levels and
different variables were assessed using the product moment
correlation coefficient (r). Univariate and multivariate
analyses were performed using the Cox proportion-hazards
model. Statistical significance was defined as p,0.05.
& RESULTS
Descriptive characteristics
We analyzed data from 101 stage I NSCLC patients
(Figure 1). All patients were of Chinese ethnicity, and most
of the patients were male (78.2%). The mean age of the
patients was 62.6¡1.37 years (ranging from 31 to 83 years).
Approximately two-thirds of the patients had a history of
smoking. Approximately half of the patients were histolo-
gically diagnosed with adenocarcinoma, and 37 (36.6%)
patients were diagnosed with squamous cell carcinoma.
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Twenty-five (24.8%) patients presented with pre-opera-
tive hypoalbuminemia. Gender, age, ECOG score, BMI,
smoking history, histological type, and tumor grade did not
significantly influence the pretreatment serum albumin
levels observed in the patients. The presence of hypoalbu-
minemia significantly correlated with larger tumor size
(p=0.026, r=20.221) and visceral pleural invasion (p,0.001,
r= 0.385). Serum albumin levels did not correlate with the
presence of lymphatic permeation and intratumoral vascu-
lar invasion (Table 1).
Correlation between serum albumin and RFS
The median follow-up was 48 months (ranging from 3 to
120 months). Twenty-two documented recurrences (21.8%)
were observed, with a median time to recurrence of 24
months (ranging from 3 to 64 months). Eleven (45.8%) of the
recurrences were distant, 10 (41.7%) of the recurrences were
locoregional and 3 (12.5%) were distant and locoregional.
The mean RFS in patients with a normal pre-operative
serum albumin level was significantly longer than the mean
RFS in patients with pre-operative hypoalbuminemia
(100.2¡5.1, 95%CI: 90.1–110.2 vs. 60.5¡7.8, 95%CI: 45.3–
75.7, p= 0.008). The 5-year recurrence-free proportion (RFP)
for patients with normal pre-operative serum albumin
levels was significantly higher than the 5-year RFP in
patients with pre-operative hypoalbuminemia (85% vs.
59%) (Figure 2A).
Similar results were obtained regarding the relationship
between post-operative serum albumin levels and RFS. The
mean RFS in patients with normal post-operative serum
albumin levels was significantly longer than the mean RFS in
patients with post-operative hypoalbuminemia (107.4¡4.8,
95%CI: 98.0–116.8 vs. 62.1¡5.6, 95%CI: 51.1–73.0, p= 0.001).
The 5-year RFP for patients with normal post-operative
serum albumin levels was significantly higher than the 5-
year RFP for patients with post-operative hypoalbuminemia
(91% vs. 62%) (Figure 2B).
Patients were divided into four subgroups according
to pre-surgical and post-surgical serum albumin levels: 1)
pre-treatment hypoalbuminemia and post-treatment
hypoalbuminemia (11 patients); 2) normal pre-treatment
serum albumin levels and post-treatment hypoalbuminemia
(37 patients); 3) pre-treatment hypoalbuminemia and
normal post-treatment serum albumin levels (14 patients);
and 4) normal pre-treatment serum albumin levels and
normal post-treatment serum albumin levels (39 patients).
The mean RFS durations for these four subgroups were 31.2,
80, 69.4 and 108.4 months, respectively (p,0.001).
Univariate and multivariate analysis of factors
associated with prognosis
The median follow-up period was 49 months (ranging
from 3 to 120 months). RFS for the entire cohort is shown in
Fig. 3. Univariate analysis identified 5 significant risk factors
for recurrence: large tumor size ($3 cm), visceral pleural
invasion, intratumoral vascular invasion, pre-operative
hypoalbuminemia, and post-operative hypoalbuminemia
(Table 2). Multivariate analysis using the Cox regression
model indicated that pre-operative hypoalbuminemia
(HR= 0.361, p= 0.028), post-operative hypoalbuminemia
(HR= 0.221, p= 0.005) and large tumor size (HR=2.059,
p= 0.038) were independent prognostic factors for
tumor recurrence (Table 3). Among the factors iden-
tified as significant predictors of tumor recurrence, post-
operative hypoalbuminemia carried the highest degree of
significance.
Subgroup analysis combining serum albumin levels
and other risk factors
Patients were divided into four subgroups according to
pre-operative serum albumin levels, post-operative serum
albumin levels and tumor size in the following manner: 1)
patients with 0 risks (27 patients); 2) patients with 1 risk (41
patients); 3) patients with 2 risks (26 patients); and 4)
patients with 3 risks (7 patients). The mean RFS durations
for these four subgroups were 109.1¡5.9 (0 risks, 95%CI:
97.4–120.7), 83.7¡3.8 (1 risk, 95%CI: 76.2–91.2), 54.7¡5.6 (2
Figure 1 - Enrollment procedure in the study.
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Figure 2 - A) Kaplan-Meier recurrence-free survival curves for 101 patients with stage I NSCLC are shown according to pre-operative
serum albumin levels (p=0.008). B) Kaplan-Meier recurrence-free survival curves for 101 patients with stage I NSCLC are shown
according to post-operative serum albumin levels (p=0.001).
Table 1 - Associations between clinicopathological characteristics and hypoalbuminemia in 101 stage I NSCLC patients
who underwent complete surgical resection.
No. of cases Hypoalbuminemia % r-value p-value*
Gender
Male 79 23 29.1 0.192 0.055
Female 22 2 9.1
Age
,65 years 33 7 21.2 0.057 0.568
$65 years 68 18 26.5
ECOG
0 or 1 80 17 21.3 0.158 0.114
2 21 8 38.1
BMI (kg/m2)
,20 29 7 24.1 20.009 0.929
$20 72 18 25.0
Smoking history
Smoker 62 19 30.6 0.172 0.085
Non-smoker 39 6 15.4
Tumor size
#2.0cm 29 3 10.3 20.221 0.026
.2.0cm #3.0cm 31 8 25.8
.3.0cm 41 14 34.1
Visceral pleural invasion
Present 21 12 57.1 0.385 ,0.001
Absent 80 13 16.3
Lymphatic permeation
Present 19 6 31.6 0.076 0.449
Absent 82 19 23.2
Intratumoral vascular invasion
Present 33 12 36.4 0.187 0.061
Absent 68 13 19.1
Histological type
Squamous cell carcinoma 37 10 27.0 0.041 0.686
Adenocarcinoma 55 13 23.6
Other 9 2 22.2
Tumor grade
G1 26 7 26.9 0.015 0.880
G2 47 11 23.4
G3 28 7 25.0
*Associations between clinicopathological characteristics and hypoalbuminemia were assessed using the product moment correlation coefficient (r).
P-values,0.05 were defined as indicative of statistical significance.
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risks, 95%CI: 43.7–65.7) and 21.9¡7.5 (3 risks, 95%CI: 7.2–
36.7) months (p,0.001). The median overall survival (OS)
durations were 26.5 (0 risks), 21.0 (1 risk), 15.0 (2 risks) and
8.5 months (3 risks) (p,0.001). The 5-year RFPs for the four
subgroups were 92% (0 risks), 91% (1 risk), 59% (2 risks) and
26% (3 risks) (Figure 4).
& DISCUSSION
Surgical resection remains the most effective treatment for
patients with early-stage NSCLC. However, the reported 5-
year survival rates of patients with stage I disease are
between 60% and 90% (26,27). The rate of recurrence in
patients with stage I NSCLC suggests that systemic tumor
cell dissemination occurs before tumor resection but
remains undetectable by current clinical techniques (28).
Based on the high frequency of recurrence in patients with
stage I NSCLC, which is presumed to be a localized disease,
several clinical trials have been conducted to analyze the
benefit of adjuvant chemotherapy for stage I NSCLC
patients who have undergone complete resection, although
the results are conflicting. A retrospective analysis per-
formed by the Cancer and Leukemia Group B (CALGB)
9633, which randomly assigned patients with stage IB
NSCLC to receive adjuvant chemotherapy or no additional
treatment, demonstrated a possible benefit for patients with
tumors larger than 4 cm but not for patients with smaller
primary tumors (29). Meta-analysis of the Lung Adjuvant
Cisplatin Evaluation (LACE) suggested a poorer outcome
for patients with stage IA tumors who received adjuvant
chemotherapy when compared with patients with stage IA
tumors who did not receive treatment (30). Thus, the current
standard of care for stage I NSCLC patients who have
undergone resection remains post-operative surveillance
regardless of the possibility of occult ‘‘micrometastatic’’
disease. If appropriate methods were available to determine
which stage I NSCLC patients would benefit from post-
operative chemotherapy, then patients with an increased
risk for recurrence could be selected for therapy and would
be expected to experience substantial clinical benefit from
adjuvant systemic chemotherapy. Therefore, methods to
definitively select stage I NSCLC patients are urgently
needed to help identify patients that are more likely to
relapse.
Serum albumin is the most abundant protein in human
blood plasma and constitutes approximately half of the
blood serum protein. Albumin transports hormones, fatty
acids and other compounds; buffers blood pH; and
maintains osmotic pressure among other functions. Serum
albumin provides a simple method for estimating visceral
protein function. Malnutrition and inflammation suppress
albumin synthesis (31). In the hospital setting, serum
albumin is used to assess patient nutritional status, disease
severity, disease progression and prognosis. Serum albumin
has also been described as an independent prognostic factor
for survival in various malignancies, such as colorectal,
gastric, breast and lung cancers (20–24).
Until recently, the clinical application of serum albumin
in the context of tumor recurrence in stage I NSCLC patients
who have undergone complete resection has rarely been
studied. This study is the first to report the prognostic value
of serum albumin levels in stage I NSCLC patients who
have undergone complete resection.
Remarkably, the presence of pre-operative hypoalbumi-
nemia significantly correlated with larger tumor size and
visceral pleural invasion. Similarly, Lohsiriwat et al. (32)
reported that in patients with rectal cancer who underwent
surgical excision, hypoalbuminemia correlated with larger
tumor size. Asher V et al. also demonstrated that pre-
operative hypoalbuminemia was associated with larger
tumor size in ovarian cancer patients (33). A mechanistic
explanation for these associations remains to be determined.
One possible explanation is that large tumors and visceral
pleural invasion cause more cancer-related symptoms,
which leads to poor food intake and protein loss through
pleural effusion. However, further studies are required to
clarify the mechanism between tumor recurrence and serum
albumin levels.
Because surgery is the standard treatment for stage I
NSCLC, we found that both pre-operative and post-
operative serum albumin levels could serve as markers that
reflect the risk of recurrence after complete resection in
patients with stage I NSCLC. The results of our study
revealed that the 5-year RFP for stage I NSCLC patients with
normal pre-operative serum albumin levels was signifi-
cantly higher than the 5-year RFP for stage I NSCLC
patients with hypoalbuminemia. Similar results were
obtained when comparing post-operative serum albumin
levels and RFP. Remarkably, patients with normal pre-
operative and post-operative serum albumin levels had the
most favorable prognoses. In addition, patients with both
pre-operative hypoalbuminemia and post-operative hypoal-
buminemia had worse prognoses. Using the Cox propor-
tional-hazards regression model for the multivariate
analysis, pre-operative and post-operative serum albumin
retained significance as independent prognostic factors for
RFS and tumor size. Several studies have demonstrated the
prognostic value of serum albumin on the OS of patients
with NSCLC. In a study analyzing prognostic factors in
patients with potentially curable lung cancer, Win T et al.
(34) reported that hypoalbuminemia is associated with poor
OS. Another study analyzing prognostic factors in patients
with advanced NSCLC conducted by the Okayama Lung
Cancer Study Group also revealed that the serum albumin
level is an independent prognostic factor (35). In addition,
Figure 3 - Kaplan-Meier recurrence-free survival curve for 101
patients with stage I NSCLC.
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Fujii T et al. (36) reported that serum albumin levels could
be used for predicting short-term recurrence in patients
with operable colorectal cancer. Although the association
between hypoalbuminemia and tumor progression remains
unclear, this association may be partially explained by the
fact that tumors interact directly and indirectly with host
inflammatory cells. As part of the systemic inflammatory
response to the tumor, pro-inflammatory cytokines and
growth factors are released, which have profound catabolic
effects on the host metabolism. The lower serum albumin
concentrations may be due to the production of cytokines
such as interleukin-6, which modulates the production of
albumin by hepatocytes. The presence of micrometastatic
tumor cells in the liver may induce Kupffer cells to produce
a variety of cytokines, which could modulate hepatocyte
albumin synthesis (37–39).
After determining the prognostic value of pre- and post-
operative serum albumin levels for recurrence and tumor
size, we further separated the patients into four subgroups
with different survival outcomes. Our results demonstrated
Table 2 - Univariate analysis of risk factors for recurrence.
Factors No. of patients Recurrence-free proportion at 5 years (%) p-value*
Gender
Male 79 76 0.153
Female 22 85
Age
,65 years 33 88 0.175
$65 years 68 74
ECOG
0 or 1 80 81 0.365
2 21 68
BMI (kg/m2)
,20 29 77 0.618
$20 72 82
Smoking history
Smoker 62 76 0.223
Non-smoker 39 82
Tumor size
#2.0cm 29 93 0.012
.2.0cm#3.0cm 31 78
.3.0cm 41 68
Visceral pleural invasion
Present 21 61 0.006
Absent 80 83
Lymphatic permeation
Present 19 77 0.943
Absent 82 84
Intratumoral vascular invasion
Present 33 70 0.027
Absent 68 83
Histological type
Squamous cell carcinoma 37 75 0.521
Adenocarcinoma 55 79
Other 9 86
Tumor grade
G1 26 75 0.244
G2 47 78
G3 28 88
Pre-operative hypoalbuminemia
Present 25 59 0.008
Absent 76 85
Post-operative hypoalbuminemia
Present 48 62 0.001
Absent 53 91
*p,0.05 was defined as indicative of statistical significance.
Table 3 - Multivariate analysis of risk factors for recurrence.
Factors Unfavorable Favorable Hazard ratio (95%CI) p-value*
Tumor size #2.0cm .3.0 cm 2.059 (1.042–4.068) 0.038
Visceral pleural invasion Present Absent 0.492 (0.187–1.294) 0.151
Intratumoral vascular invasion Present Absent 0.715 (0.277–1.841) 0.486
Pre-operative hypoalbuminemia Present Absent 0.361 (0.146–0.894) 0.028
Post-operative hypoalbuminemia Present Absent 0.221 (0.077–0.634) 0.005
*p,0.05 was defined as indicative of statistical significance.
95%CI: 95% confidence interval.
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that the combination of pre- and post-operative serum
albumin levels offered a means by which to discriminate
between stage I NSCLC patients with a higher risk for
recurrence and stage I NSCLC patients with a lower risk for
recurrence.
Limitations of our study include the relatively small study
population, which was recruited at a single institution.
However, our patient population is uniform, as the study
cohort consisted of only stage I NSCLC patients who
underwent complete resection.
Generally speaking, this study suggests that serum
albumin is a useful marker for the prediction of RFS for
patients with stage I NSCLC. The use of serum albumin
levels as a means to evaluate risk for tumor recurrence could
easily be implemented, as the test is inexpensive, rapid and
widely available in hospitals.
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